Tagged with R

UK The UK country managers of some of the biggest global pharma companies explain what it takes to manage in the UK market.   Erik Nordkamp, Pfizer Erik Nordkamp, the Dutch national serving as managing director of Pfizer UK and the newly-appointed president of the ABPI, likens managing a UK affiliate…

UK For French mid-cap Ipsen, the UK is one of three global hubs, with manufacturing in Wales, large-scale R&D activities near Oxford as well as UK Commercial Operations and global functions including HR, Tech Ops and Commercial Operations in Slough, near London. With ten percent annual growth to reach GBP 80…

UK Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of Amgen company culture.   Everyone tells you how complicated the UK market is and that is true – it’s one…

Cannabis Canadian medical cannabis company Tilray’s stock surged by over 77 percent in the first three trading days of last week before dropping dramatically by 47.9 percent to close out the week. The US Drug Enforcement Administration’s decision to allow the company to import cannabis into the USA for medical research…

Innovation “Imagine a world where every single ingredient inside every single pharmaceutical you take is traced from start to finish.” We can all agree that the healthcare system in the United States is in dire need of an overhaul. Technological advances propel us into the 21st Century, but the way data…

Turkey Fikret Baltaoglu of Laboratoires Expanscience, reveals all on the company’s recent expansion into the Turkish market after acquiring its distribution partner. He also sheds light on how the Turkish healthcare system could benefit from critical products which are not often considered to have strong ties to preventative care.   Can…

Hong Kong Wolfgang Niedermark of GIC in Hong Kong, part of the AHK network of German Chambers of Commerce worldwide assesses the business relationship between Germany and Asia and how Hong Kong compares to its regional competitors as an investment destination What is your assessment of the business relationship between Germany and…

Turkey Hasan Ulusoy, chairman of Nobel Ilac, elaborates on his company’s tremendous successes in Turkey and how they have differentiated themselves through early investment in biotechnology and firmly grasping international opportunities. Ulusoy also highlight’s Nobel’s vision for 2023 and their global ambitions. Alongside hospital products, biologicals are the next big opportunity…

Hong Kong Matthew Man, CEO of Hong Kong cold chain monitoring technology specialist Myndar, expounds on the company’s formation, its differentiating factors, and countering resistance to new innovations in the healthcare sector.   How did you identify the niche in the market for your cold chain monitoring technologies? I founded Myndar back…

Algeria Farid Benhamdine discusses the changing role of the hospital pharmacist, and the potential for a new pharmaceutical agency in Algeria. He reveals the issues this is required to solve, and the benefits he sees this bringing to the system.   The role of the pharmacist in a healthcare ecosystem is…

UK The Top 15 pharmaceutical companies in the UK in the year up to March 2018 according to IQVIA data, ranked by market share. Pfizer leads the way with a whopping 8.2% market share, followed by Novartis with 6% and GSK with 5.3%

Regulation In this exclusive interview, Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), defines ‘fair pricing’, gives the IFPMA’s take on so-called “cost-plus” pricing models, and talks about access to medicine in developing markets.   The innovative pharmaceutical industry seems to be under unprecedented pressure…